Background Advances in understanding the molecular basis of breast cancer has necessitated a definition of improved indicators of prognosis that are central to the underlying cancer biology and that reflect the heterogeneous nature of the disease. This study investigates the pattern of expression of the steroid receptor co-regulators NCOA1/SRC1, NCOA3/RAC3, NCOR2/SMRT, and CBP/ p300 in breast cancer. The aims were to identify whether their expression was related to patient outcome, their relationships to known prognostic factors and to provide a basis for further research into the mechanistic significance of such associations. Methods The protein levels of steroid receptor co-regulators were assessed by immunohistochemistry in a large well-characterised series of breast carcinomas prepared as tissue microarrays. Relationships between these targets, other clinicopathological variables and patients' outcome were examined.
Abstract
Background Advances in understanding the molecular basis of breast cancer has necessitated a definition of improved indicators of prognosis that are central to the underlying cancer biology and that reflect the heterogeneous nature of the disease. This study investigates the pattern of expression of the steroid receptor co-regulators NCOA1/SRC1, NCOA3/RAC3, NCOR2/SMRT, and CBP/ p300 in breast cancer. The aims were to identify whether their expression was related to patient outcome, their relationships to known prognostic factors and to provide a basis for further research into the mechanistic significance of such associations. Methods The protein levels of steroid receptor co-regulators were assessed by immunohistochemistry in a large well-characterised series of breast carcinomas prepared as tissue microarrays. Relationships between these targets, other clinicopathological variables and patients' outcome were examined.
Results NCOR2/SMRT was an independent prognostic indicator of overall patient survival (OS) and disease free interval (DFI) and was significantly correlated with distant metastases and local recurrence whereas tumours expressing NCOA1/SRC1 had a significantly longer OS and DFI. There were also significant correlations between co-regulator expression of NCOA1/SRC1, CBP/p300 and NCOA3/ RAC3, which were associated with lower tumour grade. NCOA1/SRC1 was also correlated with smaller tumour size. Furthermore, the co-activators had a significant association with steroid receptors, particularly ERa. Conclusions NCOR2/SMRT is associated with poor patient outcome, independent of other prognostic factors. In contrast, steroid receptor co-activator expression is generally associated with a good prognosis. Further investigations are needed to establish the mechanisms of these links between the steroid receptor co-regulator system and patient outcome.
Introduction
Breast cancer is a heterogeneous disease at the cellular and molecular level [1, 2] . It remains a crucially important goal to define more sensitive and specific indicators of prognosis that reflect the complicated and heterogeneous nature of the disease and that could identify patients at greatest risk of disease progression. Identification of the co-ordinate expression of proteins central to the underlying cancer biology could provide useful molecular markers for diagnosis and new selective targets for improved therapy.
The importance of the steroid receptors: the estrogen receptor (ER) and progesterone receptor (PgR) to the activation of steroid hormone dependent genes involved in cell proliferation, differentiation and homeostasis and to breast cancer pathology is well established [3] . The absence of PgR (like ER) has been associated with early disease recurrence and poor survival but the expression of Androgen Receptor (AR) does not appear to be an independent prognostic indicator of survival in metastatic breast cancer [4, 5] . All three nuclear receptors act as transcription factors and require the activity of two main types of nuclear receptor coregulator proteins to activate and repress target genes [6] .
Considerable attention and prognostic significance has been attached to the nuclear receptor co-regulator proteins in breast cancer [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Recent studies have shown associations between nuclear receptor co-regulators and pathoclinical parameters in breast tumours but have been limited as they have either detected mRNA or have provided limited information on relative protein levels in small numbers of samples [11] [12] [13] 15] . However, intriguing evidence indicates that an imbalance of co-activators and co-repressors may contribute to the acquisition of resistance to endocrine therapy [13] .
For nuclear steroid receptor dependent gene transcription to take place, specific members of the p160 co-activator family function as integral components of the transcriptional activation complex [19] . These include nuclear receptor co-activator 1 (NCOA1/SRC1/RIP160), nuclear receptor co-activator 2 (NCOA2/SRC2/GRIP1/TIF2), and nuclear receptor co-activator 3 (NCOA3/SRC3/AIB1/RAC3/ ACTR) as well as the co-activator CBP/p300. In the absence of oestrogen, co-repressors bind to ER and prevent activation of downstream genes by various mechanisms. These coactivators deacetylate histones; interfere with the transcriptional machinery and RNA processing, and compete with co-activators or sequester ERa in the cytoplasm [20] .
Two key co-repressors that in the absence of ligand bind to ER and mediate transcriptional repression of ER target genes are nuclear receptor co-repressor 1 (NCOR1) and its homologue nuclear receptor co-repressor 2/silencing mediator of retinoid and thyroid receptors (NCOR2/ SMRT). These form complexes with NCOA3, with histone deacetylases and they maintain chromatin in a transcriptionally inactive state. The co-repressor NCOR2/SMRT has been reported in the nuclei of breast cancer cells [9, 10] . It binds histone deacetylase-3 [6, 20] which catalyses the removal of acetyl groups from histones. It is thought that NCOR2/SMRT also mediates the activity of anti-oestrogens [20] , and indeed, ER recruitment of NCOR2/SMRT is vital for full antagonist function of tamoxifen [10] .
In the current study, we have assessed the protein levels of the nuclear receptor co-regulators NCOA1/SRC-1, NCOA3/AIB1, CBP/p300 and the co-repressor NCOR2/ SMRT in the largest number of breast tumour samples (n = 560) to date. We have employed tissue microarray technology and immunohistochemistry to relate the expression of these to various patho-clinical parameters and survival outcomes. The expression of these co-regulators was also compared with that of steroid receptors and other biomarkers. We show that NCOR2/SMRT is an independent prognostic indicator in breast cancer and that the level and pattern of co-ordinate expression could refine human breast cancer classification, predict clinical outcome and provide the basis for research to identify new biomarkers to assist with diagnosis and new anti-cancer therapies.
Experimental procedures

Patients
The patient cohort comprised 560 primary operable invasive breast carcinoma cases from women presenting between 1986 and 1998, selected from the well-characterised Nottingham Tenovus Primary Breast Carcinoma Series. All patients had been assessed in a standardised manner for clinical history and tumour characteristics including age, menopause status, tumour type [21] , histological grade [22] , tumour size, tumour recurrence, presence of distance metastasis, lymph node status, vascular invasion and Nottingham Prognostic Index (NPI) [23] . Data relating to survival was collated in a prospective manner; including survival time, defined as the interval (in months) from the date of the primary treatment to the time of death, and disease free interval, defined as the interval (in months) from the date of the primary treatment to the first loco-regional recurrence or distant metastasis. Patient management was based on tumour characteristics by NPI and hormone receptor status. Patients with an NPI score £3.4 received no adjuvant therapy, those with a NPI score ([3.4 received Tamoxifen if oestrogen receptor (ER) positive (±Zoladex if pre-menopausal) or classical cyclophosphamide, methotrexate and 5-fluorouracil if ER negative and fit enough to tolerate chemotherapy [4] .
Of the 560 in the cohort, 375 patients were aged over, and 181 under, fifty years old (n = 4 of unknown age), with a median age of 55 years. Those with a pre-menopausal status accounted for 197 of the cohort, with 339 postmenopausal (n = 3 of unknown status). The cohort had varied disease characteristics; with 104 (19%) of cases Grade 1, 179 (32%) Grade 2, and 272 (49%) were Grade 3. At primary diagnosis 190 (34%) of patients were lymph node positive, 170 (30%) had positive vascular invasion, and 379 (68%) had a tumour sized greater than 1.5 cm. Frequencies for histological tumour type were: Invasive ductal/No Special Type (NST) n = 322, Tubular mixed n = 108, Medullary n = 21, Lobular n = 49, Tubular n = 12, Mucinous n = 5, Invasive cribriform n = 3, Mixed NST and lobular n = 18, Mixed NST and special type n = 14 and other rare types n = 4. Initial follow-up was at 3 months, followed by 6 monthly and then annually, with the median follow-up period of the patient 86 months (range 1-192 months), during which period, recurrence occurred in 154 (28%) of cases, distant metastases occurred in 84 cases (15%), and 75 (13%) patients died from breast cancer. The immunostaining, scoring and categorisation of ER, PgR, AR, cytokeratin (Ck)5/6, Ck14, Ck18, Ck19, HER2, p53, BRCA1, basal-like and triple-negative phenotypes were as previously described [24] [25] [26] [27] .
This research was approved by Nottingham Research Ethics Committee 2 under the title of ''Development of a molecular genetic classification of breast cancer''.
Tissue microarrays (TMA) and immunohistochemistry
Breast cancer tissue microarrays were prepared and immunohistochemistry carried out employing the standard streptavidin-biotin complex method as previously described [4] . Primary antibodies used were: CBP/P300 (c-1, diluted 1:200 in NSS, Santa Cruz Biotechnology, Inc., Santa Cruz, CA); NCOA1 (1/NcoA1, diluted 1:25 in NSS, Abcam Ltd, UK using EDTA pH8.0 for antigen retrieval); NCOA3 (C-20, diluted 1:50 in NSS, Santa Cruz Biotechnology, Inc.); NCOR2 (1542/H7, diluted 1:100 in NSS, Santa Cruz Biotechnology, Inc.) all for 45 min except NCOA3 which was incubated for 2 h at room temperature.
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0 Diaminobenzidine tetrahydrochloride (Dako liquid DAB plus, K3468, Denmark) was used as a chromagen. The sections were counterstained with Mayer's haematoxylin. Positive and negative controls for each marker were used according to the supplier's data sheet. In addition, whole tissue sections from representative breast tumours were also analysed to assess and validate the pattern of expression of the biomarkers.
Immunohistochemical scoring
The modified Histo-score (H-Score) was utilised to quantify nuclear staining (for NCOA1/SRC1, CBP/p300 and NCOR2/SMRT) or cytoplasmic staining (for NCOA3/ RAC3) of the TMA cores [28] . The range of possible scores is 0-300. Only staining of the invasive malignant cells within the tissue cores was considered. All samples were scored by one observer (CB) and a proportion of these counter-scored by two further observers (ARG and CJG) to ensure reproducibility.
Statistical analysis
Statistical analysis was carried out using SPSS 12.0.1 statistical software. Frequency histograms were examined to group the data into expression groups, which were used throughout the analyses. Chi-squared analyses were used for inter-relationships between steroid receptor co-regulators and for comparison with patho-clinical parameters, steroid receptors and biomarkers. The Kaplan-Meier method was used for the calculation of survival curves and disease free interval analyses. Cox proportional hazards model was used to test the statistical independence and significance of predictors on relapse-free interval (RFI) and the overall survival. A P-value of \0.05 was considered significant.
Results
In order to determine whether protein levels of the nuclearreceptor co-regulators could improve breast cancer classification and assessment of prognosis we investigated the co-ordinate expression of NCOA1/SRC1, CBP/p300, NCOA3/RAC3 and NCOR2/SMRT in a large cohort (n = 560) of breast tumours. We aimed to establish whether the co-regulators were co-ordinately expressed; associated with levels of other biomarkers; and/or were prognostically significant. For NCOA1, CBP/p300, NCOA3 and NCOR2 the number of informative cases were 426, 314, 278 and 235 respectively after excluding the uninformative TMA cores, which were either lost/fragmented during the immunohistochemical procedure or did not have invasive tumour.
Steroid receptor co-regulator expression in breast tissue
Immunohistochemical assessment of whole breast tissue sections revealed positive expression of the steroid receptor co-regulators CBP/p300, NCOR2/SMRT and NCOA1/ SRC1 localised to the nucleus, whilst NCOA3/RAC3 exhibited predominately granular cytoplasmic staining with little or no nuclear staining (Fig. 1) . Staining of both NCOA3/RAC3 and NCOA1/SRC1 was homogenous, whereas CBP/p300 and NCOA1/SRC1 showed heterogeneous staining levels. Normal breast epithelium was also positive for NCOA3/RAC3, CBP/p300, NCOR2/SMRT and NCOA1/SRC1, but surrounding stromal cells were positive for only CBP/p300 and NCOR2/SMRT (data not shown).
Steroid receptor co-regulator expression in breast cancer
Data were categorised into three groups according to frequency distributions for: CBP/p300 and NCOA3/RAC3, negative/weak (H-score \ 100), moderate (H-score ‡100 and \200) and strong (H-score ‡ 200) expression; NCOA1/SRC1 negative/weak (H-score \ 50), moderate (H-score ‡ 50 and \150) and strong (H-score ‡150) expression. In the case of NCOR2/SMRT, expression was dichotomised into negative (H-score £50) and positive (Hscore [50) expression (Table 1) . A total of 74.7% of samples expressed NCOA1, the majority of which showed moderate expression (49.3%). CBP/p300 expression was found in 63.7% of tumours the majority of which expressed the co-activator moderately (52.9%). An overwhelming majority of the tumours studied for NCOA3/RAC3 expression showed positive expression (97.4%) with moderate staining accounting for 82.7% of samples. The co-repressor NCOR2/SMRT was only expressed in a total of 16.7% of tumours.
Significant correlations were found between expression of the co-regulators CBP/p300, NCOA3/RAC3, NCOR2/ SMRT and NCOA1/SRC1, which are summarised in Table 2 . Strong positive associations between NCOA1/ SRC1 and the other co-regulators, CBP/p300, NCOA3/ RAC3 and NCOR2/SMRT, were observed (P £ 0.004). Furthermore, NCOA3/RAC3 was associated with both CBP/p300 and NCOR2/SMRT expression (P £ 0.005). There was no correlation between NCOR2/SMRT and CBP/p300 expression. Correlation of steroid receptor co-regulator expression with patho-clinical parameters
To determine the clinical significance of steroid receptor co-regulators correlations between their protein expression and prognostic patho-clinical parameters were investigated. Several significant correlations were observed (Table 3) .
Expression of NCOA1/SRC1 and CBP/p300 was associated with tumour type particularly ductal carcinoma of no special type (duct/NST), lobular and tubular mixed tumours (P \ 0.001 and P = 0.034, respectively, data not shown). NCOA1/SRC1, CBP/p300 and NCOA3/RAC3 showed significant correlation with tumour grade, with those expressing the co-activators having lower grade tumours (p \ 0.001, p = 0.012 and P \ 0.001 respectively). NCOA1/SRC1 was also associated with smaller tumour size (£1.5 cm, P \ 0.001) and showed a trend with lack of distant metastases and recurrence (P = 0.050 and P = 0.022, respectively). CBP/p300 and NCOA3/RAC3 showed no correlation with tumour size, distant metastases or recurrence. Although NCOR2/SMRT showed no correlation with grade or tumour size, it showed significant positive association with recurrence (P = 0.009), particularly local recurrence (P \ 0.001) and distant metastases (P = 0.041). No significant correlations were found between any of the co-regulators and menopausal status, age, lymph node stage, vascular invasion, regional recurrence or distant metastasis site (data not shown).
Selective associations of co-regulators with steroid receptor protein levels
Given that the activity of NCOA1, NCOA3, CBP/p300 and NCOR2 are key factors in determining the level of steroiddependent gene expression, the relationships between steroid receptor co-regulator expression and steroid receptors (ERa, PgR and AR) were examined (Table 4 ). There was a significant positive correlation between NCOA1/SRC1 expression and all steroid receptors investigated; ERa (P \ 0.001), PgR (P = 0.004) and AR (P \ 0.001). The other co-activators investigated: CBP/p300 and NCOA3/ RAC3, showed more variable correlations with the steroid receptors; CBP/p300 was found to have a significant positive correlation with ERa (P = 0.004) and PgR (P = 0.002) but not with AR. In the case of NCOA3/ RAC3, a significant positive correlation was found with ERa ( P = 0.037) and AR (P = 0.005) only. Whilst a trend was evident for breast tumours that expressed NCOR2/ SMRT to express ERa, this did not reach significance at the 5% level and there was no significant association with PgR and AR.
Steroid receptor co-regulators levels are linked with BRCA1 but not p53, c-erbB2/HER2 or basal-like phenotype Based on our previous work, specific biomarkers of breast cancer were selected and examined in our patient tumour cohort as is summarised in Table 4 [14] . There were no significant correlations between any of the co-regulators and cytokeratin expression (ck5/6, ck14, ck18 and ck19), except for NCOA1/SRC1, which was associated with luminal cytokeratin 18 and inversely correlated with the basal cytokeratins 5/6. Despite this, NCOA3/RAC3 expression was significantly expressed in tumours with the basal-like phenotype (those tumours showing basal epithelial characteristics which are associated with a poor outcome; P = 0.028). There were no associations between any of the co-regulators and p53 or c-erbB2/HER2 expression, whilst negative NCOA1/SRC1 and CBP/p300 expression were absent from the triple-negative (ER -, PgR -and HER2 -) phenotype. However, interestingly, a statistically significant positive correlation was found between BRCA1 and all four co-regulators; NCOA1/SRC1 (P \ 0.001), CBP/p300 (P = 0.026), NCOA3/RAC3 (P \ 0.001) and NCOR2/SMRT (P = 0.031).
NCOA1/SRC-1 and NCOR2/SMRT are associated with patient outcome Of the co-regulators studied, two showed significant associations with patient outcome (Fig. 2) . Tumours expressing NCOA1/SRC1 had a longer overall survival (OS) (LR = 7.45, P = 0.0266) and a longer disease free interval (DFI) (LR = 7.26, P = 0.0242). There was clear distinction between those strongly expressing NCOA1/SRC1 who had a longer survival than those with moderate expression, who in turn had longer OS than those with negative expression. Similar division of expression levels were observed for DFI, with the strongest NCOA1/SRC1 expression relating to the longest the DFI. Conversely, those expressing NCOR2/SMRT had a shorter OS (LR = 5.60, P = 0.0180) and a shorter DFI (LR = 7.69, P = 0.0056). CBP/p300 and NCOA3/RAC3 showed no correlation with either OS or DFI. In multivariate Cox hazard analysis, NCOR2/SMRT was a significant predictor of longer OS and DFI independent of tumour grade, lymph node status, size, hormone receptor and HER2 status (Table 5 ).
Discussion
Recently, there has been a wealth of studies investigating the prevalence and role of steroid receptor co-regulators in breast cancer [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Suggestions have been made pertaining to their importance in breast cancer development, progression, and their prognostic significance in terms of outcome and treatment response, but there seems to be no clear consensus between studies. In this study, expression levels of four such co-regulators: NCOA1/SRC1, CBP/ p300, NCOA3/RAC3 and NCOR2/SMRT, were determined in a large cohort of breast tumour samples. Their associations were analysed in relation to various clinical and pathological parameters, as well as to expression levels of the nuclear receptors ERa, PgR and AR, and various biomarkers. This is the largest study to date of this kind, in terms of sample size, and in addition has greater clinical relevance than previous studies by investigating in situ protein levels rather than mRNA levels or gene amplification, or performing in vitro experiments as in previous studies [9, 10, 13, 14, 17, 18] . Immunohistochemistry was used to explore protein expression in breast cancer TMAs, which were analysed by the H-score method. TMAs have been widely established as reliable and enable highthroughput simultaneous analysis of a large number of tumour samples [29, 30] . The H-score too has been demonstrated to be reliable and produce equivalent results to other immunohistochemical scoring methods [28] .
As anticipated, the study found protein expression of NCOA1/SRC1, CBP/p300 and NCOR2/SMRT to be localised in the nucleus. Conversely, NCOA3/RAC3 staining was found to be almost exclusively cytoplasmic. This is a point of controversy in the literature, with some studies reported NCOA3/RAC3 staining to be predominantly nuclear [11, 15] , while others reported cytoplasmic staining, as determined in this study [14, 16] . Indeed, List et al. suggested a trend that with increased progression of breast cancer, NCOA3/RAC3 localisation becomes more nuclear than cytoplasmic [16] . This was not shown in the current study where only 9 of 278 tumours showed nuclear staining (data not shown RAC3 with cytoplasmic proteins. Transcription factors such as BRCA1 as described by Chen et al. [15, 31] was found in the cytoplasm reportedly due to inactivation and mis-localisation. Significant positive correlations were found among several of the co-regulators in breast cancer, suggesting considerable co-expression of these proteins. The correlation between NCOA1/SRC1 and CBP/p300 conflicts with Kurebayashi et al. (2000) who found no relationship [9] . Their use of RNA expression, rather than protein levels, to determine co-regulator expression may explain this discrepancy. The association between NCOA3/RAC3 and CBP/p300 has been previously demonstrated [9, 15] and is supported by Torchia et al. [19, 32] who suggest that a significant fraction of NCOA3/RAC3 and CBP/p300 protein combine to form a functional complex, with NCOA3/ RAC3 phosphorylation stimulating CBP/p300 recruitment [33] . Their interaction is synergistic, with the presence of both co-activators required for full function of the complex in transcriptional activation of target genes [19, 32] . Coexpression of NCOR2/SMRT with NCOA1/SRC1 and NCOA3/RAC3 suggests that the activity of the co-repressors is balanced by that of the other co-activators, or vice versa, thereby strictly controlling steroid receptor transcriptional activity.
Relationships between the co-regulator levels and several clinical parameters were determined, suggesting the co-regulators could prove to be useful prognostic factors. High levels of all three co-activators studied, particularly NCOA1/SRC1 were found to be significantly correlated with good prognostic factors including low tumour grade, smaller tumour size, lack of metastasis together with ER, PgR and luminal phenotype. Studies using mRNA or small sample sizes have found associations between CBP/p300 [9] or NCOA1/SRC1 [10] and lymph node positivity, however this study, in concurrence with Hudelist et al. [15] , who found no correlation between any of the coregulators studied and lymph node status. In addition, Hudelist et al. [15] found a correlation between co-activators and tumour grade, though only for NCOA3/RAC3, possibly explained by their small sample size and more standardised patient characteristics. Furthermore there is evidence for a correlation between NCOA1/SRC1 and tumour grade [11, 14] . However, our study has a considerably larger sample size compared with previous studies, giving much greater reliability to the results. In contrast to the co-activators, although the co-repressor NCOR2/SMRT did not show any correlation with grade, size or stage, we found it was associated with poorer prognostic factors particularly both local recurrence and distant metastases.
There seems to be no consensus in the literature as to the relationships between steroid receptor expression and that of co-regulators. Suggestions of independence of co-regulator and ERa [9, 13, 15] and PgR [15, 17] expression is questioned by Fleming et al. [10] who found co-localisation of NCOA1/SRC1 and NCOR2/SMRT with ERa, and other evidence supporting the positive relationship found between PgR and NCOA1/SRC1 and CBP/p300 [14] . Interestingly, Iwase et al. [14] found no correlation between NCOA3/RAC3 mRNA and ERa, but when they looked at NCOA3/RAC3 protein expression, they found a significant positive correlation with ERa; demonstrating the value of studying actual protein levels rather than mRNA levels. The association between steroid receptors and their co-regulators can be expected, particularly as Smith et al. (1996) showed NCOA1/SRC1 and CBP/p300 to act synergistically in their activation of ER and PgR by stabilising the interaction with their ligands [9, 34] . Although some authors [35] failed to find a correlation between NCOA1/SRC1and ERa, (this cannot be correlated with the biological functions of these markers. In fact, one would expect a co-activator to be correlated with its target, and additionally may explain their survival finding, as ERnegative tumours are associated with factors linked to a poorer prognosis than ER-positive tumours.
Interestingly, we found an association between strong BRCA1 expression and high levels of all the co-regulators investigated (NCOA1/SRC1, CBP/p300, NCOA3/RAC3 and NCOR2/SMRT), which may indicate a biological interaction between BRCA1 and these co-regulators. This can also supported by the previous study of Fan et al. who demonstrated a physical and functional interaction between CBP/p300 and BRCA1 and suggested that co-factors, such as CBP/p300, can modulate the repression of ERa activity via BRCA1 [36] .
This study further demonstrates that NCOA1/SRC1 and NCOR2/SMRT, though not CBP/p300 and NCOA3/RAC3, to be predictive of patients' outcome; with high NCOA1/ SRC1 significantly associated with longer OS and DFI irrespective of systemic treatment, and high NCOR2/ SMRT predictive of poorer survival and a shorter DFI. Although, in a previous study, Myers et al. reported an association between high NCOA1/SRC1 levels and factors suggestive of a poor prognosis, such as shorter DFI [13] , there are considerable differences between their study and the current one. They looked at a much smaller sample size with a considerably shorter follow-up (median follow-up 27 months compared to 86 months for our cohort) and used a standardised cohort with all patients receiving hormone therapy and chemotherapy. On multivariate Cox regression analysis, NCOR2/SMRT expression was found to be an independent prognostic factor for patient outcome.
In conclusion, this is the first study that demonstrates steroid receptor co-activator expression is generally associated with a good prognosis whereas the co-repressor NCOR2/SMRT is associated with poor patient outcome in terms of recurrence. Further investigations are therefore needed to establish the mechanisms of these links between the steroid receptor co-regulator system and patient outcome.
